Clinical Trial Update: Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the combination of zanubrutinib and lisocabtagene maraleucel for Richter's syndrome, with patient recruitment ongoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma
• Richter Syndrome

Drugs mentioned

• Lisocabtagene maraleucel (lisocabtagene maraleucel)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Aseel Alsouqi | Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 2 | Status: RECRUITING